Carvedilol maintained left ventricular ejection fraction at 63.88%, while control significantly decreased to 60.82% (P=0.003) in patients receiving adriamycin chemotherapy.
RCT (n=54)
null
null
No
Does prophylactic carvedilol prevent adriamycin-induced left ventricular systolic dysfunction in patients with haematological malignancies?
Prophylactic use of low-dose carvedilol preserves left ventricular systolic function in patients receiving anthracycline chemotherapy.
Effect estimate: null (95% CI null)
Absolute Event Rate: 63.88% vs 60.82%
p-value: p=0.003
Background P < 0.05). Interpretation & conclusions: Prophylactic use of carvedilol in patients receiving anthracycline protected systolic functions of the left ventricle. Carvedilol can be a potential drug which can ameliorate ADR-induced CMP.
Jhorawat et al. (Tue,) conducted a rct in adriamycin-induced cardiomyopathy (n=54). carvedilol vs. control was evaluated on left ventricular ejection fraction (null, 95% CI null, p=0.003). Carvedilol maintained left ventricular ejection fraction at 63.88%, while control significantly decreased to 60.82% (P=0.003) in patients receiving adriamycin chemotherapy.